Delamanid-based Regimen (longer course)
Treatment for Multidrug-resistant tuberculosis without extensive drug resistance
Typical Dosage: Delamanid 100mg twice daily for 6 months, combined with other second-line drugs for full duration
Effectiveness
78%
Safety Score
60%
Clinical Trials
30
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Delamanid 100mg twice daily for 6 months, combined with other second-line drugs for full duration
Time to Effect
2-3 months for culture conversion
Treatment Duration
18-24 months
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$14,000
Monitoring:$4,000
Side Effect Mgmt:$2,500
Total Annual:$20,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
0.65
Outcome-Based Costs
Cost per Responder
$26,282
Cost per Remission
$28,082
Comparison vs Injectable-containing MDR-TB regimen
Cost Difference
+$1,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Delamanid-based Regimen (longer course) Outcomes
for Multidrug-resistant tuberculosis without extensive drug resistance
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+78%
Remission Rate
+73%
Common Side Effects
QT prolongation (Delamanid)
+15%
Nausea/Vomiting
+10%
Headache
+8%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov